Clinical trials: Non-Diabetic
Diabetic Foot Ulcers
dHACM Mesh In the Treatment of Diabetic Foot Ulcers
A single-centered, non-randomized study with approximately 20 subjects that will be seen for up to 12 weeks, each receiving the EpiFix mesh plus standard of care. Safety and effectiveness will be monitored throughout the study.
- Trial name
- NCT02589210
- Testing
- EpiFix Mesh
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- MiMedx Group, Inc.
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Multi-Parametric MRI Assessment of the Liver in Diabetic Volunteers (Partners Registry)
To build a registry of diabetic volunteers by inviting them to get a LiverMultiScan and collecting their contact information to seek interest in participating in future research studies.
- Trial name
- NCT04336800
- Testing
- LiverMultiscan
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Perspectum
Hyperlipidemia
Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
- Trial name
- PLANET II (NCT00296400)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 107 sites in United States, Brazil and 9 more
- Volunteers
- 237 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes
This study is conducted in Africa, Asia and Europe. The aim of this study is to investigate biphasic insulin aspart 30 (NovoMix® 30) alone or in combination with oral hypoglycaemic agent (OHA) for type 2 diabetes management in…
- Trial name
- PRESENT (NCT01536600)
- Testing
- biphasic insulin aspart 30
- Where
- South Korea
- Volunteers
- 33,010 people
- Sponsor
- Novo Nordisk A/S
Dyslipidemia
Safety Study of BMS-823778 in Subjects With Hypercholesterolemia
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
- Trial name
- NCT01112423
- Testing
- BMS-823778
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Diabetic Retinopathy
HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia
This is a study in people with a type of diabetic eye disease called diabetic retinopathy with diabetic macular ischemia. People who have had laser treatment for their diabetic retinopathy can participate in the study.
- Trial name
- HORNBILL (NCT04424290)
- Testing
- BI 764524
- Where
- 19 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
Diabetic Foot Ulcer
Study of Oasis Ultra in Diabetic Foot Ulcers
Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra.
- Trial name
- NCT01835379
- Testing
- Oasis, Standard
- Where
- 16 sites in United States
- Volunteers
- 82 people
- Sponsor
- Healthpoint
Endometriosis Related Pain, Overactive Bladder
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
Researchers are looking for a new way to treat people suffering either from a condition where the bladder is unable to hold urine normally (overactive bladder), or a condition in which tissue similar to the tissue that normally…
- Conditions
- Endometriosis Related Pain, Overactive Bladder, Diabetic Neuropathic Pain, Refractory or Unexplained Chronic Cough
- Trial name
- NCT04487431
- Testing
- BAY1817080, [14C]BAY1817080
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Bayer
Non-Proliferative Diabetic Retinopathy, Cataract
Nepafenac Once Daily for Macular Edema - Study 2
The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic participants following cataract surgery.
- Trial name
- NCT01872611
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Vehicle, Prednisolone acetate
- Volunteers
- 819 people
- Sponsor
- Alcon Research
Diabetic Foot Ulcer
Adipose Derived Regenerative Cells In the Treatment of Diabetic Foot Ulcers
A Prospective, Double-blind, Multi-center, Randomized, Parallel-group safety and efficacy study of adipose-derived regenerative cells (ADRCs) in the treatment of patients with diabetic foot ulcers (DFU).
- Trial name
- ASCEND (NCT05095389)
- Testing
- ADRCs, standard care
- Volunteers
- 290 people
- Sponsor
- Paracrine, INC.
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00130845
- Testing
- Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Novartis
Non-Proliferative Diabetic Retinopathy
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
The goal of this clinical trial is to learn if drug TNTL works to treat non-proliferative diabetic retinopathy in adults. It will also learn about the safety of drug TNTL. The main questions it aims to answer are: 1.
- Trial name
- TNTL (NCT06817265)
- Testing
- TNTL, TNTL simulation preparation
- Where
- 30 sites in China
- Volunteers
- 360 people
- Sponsor
- Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Overweight , Obesity
Phase 2 Study of MWN109 Tablet in Participants With Overweight or Obesity
This is a phase II, multicenter, randomized, double-blind, placebo-controlled clinical trial to preliminarily evaluate the efficacy, safety, and PK of MWN109 tablets administered orally once daily in non-diabetic participants…
- Trial name
- NCT07791524
- Testing
- MWN109 1, MWN109 2, MWN109 3
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Diabetic Macular Edema
A Real-world Study to Assess Safety of OZURDEX® (Dexamethasone Intravitreal Implant) in Adult Participants With Diabetic Macular Edema in China
The dexamethasone intravitreal implant (OZURDEX) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of diabetic macular edema (DME).
- Trial name
- NCT06548568
- Where
- 13 sites in China
- Volunteers
- 110 people
- Sponsor
- AbbVie
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL
The purpose of this clinical evaluation is to collect patient outcome data and evaluate the efficacy, safety and tolerability of HealthTech DermaBind TL™ in patients with chronic non-healing wounds in patients with chronic…
- Trial name
- NCT07172893
- Testing
- DermaBind TL
- Where
- 10 sites in United States
- Volunteers
- 150 people
- Sponsor
- HealthTech Wound Care
Non Healing Diabetic Foot Ulcer
Comparing Wound Area Reduction of Non-healing DFUs Using MolecuLight i:X Versus Standard of Care
This is a 12 week, randomized controlled trial. There are 2 arms and 20 patients with non healing diabetic foot ulcer allocated in each arm.
- Trial name
- WAR (NCT04207099)
- Testing
- MolecuLight i:X Imaging Device
- Where
- 3 sites in United States
- Volunteers
- 61 people
- Sponsor
- MolecuLight Inc.
Diabetes, Foot Ulcers
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
Primary objective To assess wound healing and granulation tissue formation when using the NPWT system Secondary objectives To investigate the pain level at dressing removal To visually check exudate removal To investigate the…
- Trial name
- NCT01011387
- Testing
- NPWT System
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Molnlycke Health Care AB
Diabetes
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
This study is an extension of a study that has been ongoing for 1 year. The purpose of this open label study is to see the how well type 2 diabetics respond to VI-0521(phentermine/topiramate) in controlling blood sugar and how…
- Trial name
- NCT00737633
- Testing
- VI-0521
- Where
- 9 sites in United States
- Volunteers
- 101 people
- Sponsor
- VIVUS LLC
Painful Diabetic Peripheral Neuropathy
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
This study is to test the effectiveness of pregabalin in treating nerve pain caused by diabetes. The suitable subjects will be patients who also use an non-steroid anti-inflammatory drug for another pain which is not related to…
- Trial name
- NCT01455415
- Testing
- pregabalin
- Where
- 61 sites in United States, Czechia and 2 more
- Volunteers
- 306 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.